With help from Biomedtracker, Scrip takes a look at six drug candidates expecting pivotal data by the end of the year. The assets span a range of therapeutic areas, from ophthalmology to neurology, and are poised to become market firsts, rivals to dominant products or win important label expansions.

Public Company Edition: Valuations have fallen enough in 2022 to lead some companies to wind down operations, but a recent uptick opened a window for a few offerings. Chinook raised $105m in a follow-on offering, while Flagship led a $79.2m registered direct offering for Evelo.

Only two new antibiotics are in Phase III trials for gonorrhea: Entasis’ zoliflodacin, in collaboration with the Global Antibiotic R&D Partnership, and GlaxoSmithKline’s gepotidacin in partnership with the US Biomedical Advanced R&D Authority.

After launching albuterol, India's Lupin is seeking to expand its presence in the respiratory market. With generic Fostair set for a European launch in fiscal 2022 and Spiriva for a US introduction the following fiscal year, the company is counting on the portfolio to deliver growth from the coming financial year.